Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Open-Label, Two-Period, Two-Sequence, Single-Dose, Crossover Bioequivalence Study of Methylconalamin Injection and Methylconalamin for Injection in Healthy Subjects Under Fasting Conditions

NCT07158099 is registered in ClinicalTrials.gov with Wanbangde Pharmaceutical Group Co., LTD as lead sponsor.

NCT NCT07158099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07158099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Open-Label, Two-Period, Two-Sequence, Single-Dose, Crossover Bioequivalence Study of Methylconalamin Injection and Methylconalamin for Injection in Healthy Subjects Under Fasting Conditions
Lead sponsor
Wanbangde Pharmaceutical Group Co., LTD
Phase
Phase 1
Overall status
Completed
Start date
September 10, 2025
Completion date
September 29, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

therapeutic equivalency, healthy